Texas Is Quietly Building the Case for Another THC Crackdown
Senate Health and Human Services Committee given interim charge
The next major fight over hemp-derived THC in Texas is already taking shape, and it is not beginning with a neutral policy review. It is unfolding just as the industry’s legal team prepares to challenge the Department of State Health Services’ permanent hemp rule in court, with lawyers arguing that the agency repeated the same kind of administrative overreach at issue in the Sky Marketing litigation and again tried to do by rule what Texas law did not authorize it to do by statute. In that telling, the state did not simply adopt an aggressive interpretation of its power. It used bureaucratic means to pursue a prohibitionist outcome that critics say could not be cleanly achieved through the ordinary constitutional process. Against that backdrop, Lieutenant Governor Dan Patrick’s new interim charge to the Senate Health and Human Services Committee looks less like an open inquiry than the next move in a coordinated campaign.
The charge directs lawmakers to study the “societal impacts” of THC product consumption, with particular emphasis on increased health care costs, mental health emergency detentions, THC-induced psychotic disorder, and criminal justice burdens. What it does not ask is just as revealing. It does not ask whether Texas has created a workable regulatory framework for lawful hemp products. It does not ask whether patients and consumers retain meaningful access. It does not ask whether DSHS exceeded its statutory authority. And it does not ask whether prohibition would impose costs of its own. The structure of the assignment points in one direction: build a record of harm, quantify the burden, and prepare the argument for a more aggressive legislative response in 2027.
That is why this development should be understood as more than another committee study. In Texas politics, the decisive work often begins long before a bill is filed. Interim charges shape hearings, hearings shape reports, and reports become the respectable-looking foundation for policies whose conclusion was plain from the start. Here, the real question does not appear to be what kind of hemp policy Texas needs. It appears to be how much damage THC can be made to represent on paper.
The Committee Leadership Tellst The Story
Lois Kolkhorst is central to this process not because she is the Senate’s most theatrical prohibitionist, but because she is something more consequential: a disciplined institutional loyalist with a long record of aligning herself with leadership when it matters. Her history on cannabis policy shows occasional room for tightly cabined compassionate-access arguments, but little evidence of any appetite to break with the Senate’s power structure.
As a House committee chair, she allowed a harsher marijuana-related measure to die without advancing it, then later voted for the Compassionate Use Act. That record did not make her a reformer. It made her a politician willing to permit narrow exceptions without becoming the architect of broader change. When the decisive test arrived in the 89th Legislature, she voted for SB 3, the Patrick-backed total THC ban later vetoed by Governor Abbott. There is no indication she tried to soften its essential purpose or publicly distance herself from its prohibitionist thrust.
Just as important, Senator Charles Perry serves as vice chair of the committee. The Texas Senate’s official materials identify Perry as vice chair of Health and Human Services, alongside Kolkhorst as chair. That is not a minor organizational detail. Perry has spent years positioning himself as one of the hemp industry’s most consistent antagonists, and his presence in the committee’s second-ranking role signals that this will not be a neutral venue. If Kolkhorst embodies the institutional discipline of Senate leadership, Perry brings the ideological zeal. Together they form a leadership structure far more likely to treat hemp-derived THC as a target to be suppressed than a market to be sensibly regulated.
That matters because hearings are not passive events. Chairs and vice chairs shape tone, sequence witnesses, frame questions, and decide what kinds of testimony are treated as serious. On an issue as contested as hemp-derived THC, that kind of procedural control can matter as much as any floor vote.
Dan Patrick’s Method Is Becoming Plain
Seen in sequence, the pattern is getting harder to ignore. Since 2025, the anti-THC campaign in Texas has moved on several fronts at once. The Legislature established the rhetoric. The executive and administrative apparatus imposed immediate burdens. Now the interim study process is being positioned to generate the official record that can be cited when lawmakers return in 2027.
This is how a durable prohibition agenda is assembled. First comes the moral panic. Then come the regulatory burdens. Then comes the official study that translates political claims into findings, recommendations, and citations suitable for legislation. By the time the next bill is filed, its supporters can present the outcome not as ideology, but as the sober conclusion of a state-sanctioned review. That is the political value of a charge like this one. It allows a predetermined conclusion to wear the costume of public-health diligence.
Why the Timing Matters
The timing is especially revealing. Texas has just finalized DSHS permanent rules that took effect at the end of March 2026, and those rules are already facing legal challenge over whether the agency exceeded its authority, particularly in its treatment of total THC and THCA. The dispute is not merely technical. It goes to whether an agency can effectively redraw the legal boundaries of the hemp market through rulemaking when the Legislature itself did not clearly do so.
From that perspective, Patrick’s interim charge looks like a hedge as much as a study. If the courts conclude that DSHS overreached, the Legislature will want a ready-made predicate for direct statutory action in 2027. A committee record saturated with testimony about psychosis, emergency detentions, and public cost would serve that purpose well. It prepares the ground for the next prohibition push in case the current regulatory approach proves legally unstable.
Kolkhorst’s Expanded Influence Raises the Stakes
The memo’s most significant observation may be that Kolkhorst’s power now extends beyond this single interim charge. She was also appointed to chair the Sunset Advisory Commission at a moment when agencies including the Health and Human Services Commission and DSHS will be under review. That creates a notable concentration of authority in one senator already closely aligned with Senate leadership and now positioned at the center of both the THC study and the broader institutional review of the agencies shaping hemp regulation.
That dual role matters because it links narrative power with procedural power. The same political ecosystem that will study THC’s alleged harms will also be positioned to evaluate the agencies enforcing the state’s hemp rules. For the hemp industry and for the broader public, the question is whether that concentration of influence will produce meaningful scrutiny of agency overreach or simply a more coordinated effort to ratify it.
Federal Pressure May Tighten the Squeeze
The state fight is also unfolding against a shifting federal backdrop. The memo notes that a federal continuing resolution provision set to take effect in November 2026 could move federal policy toward a total-THC standard and push many intoxicating hemp products back toward Schedule I treatment under federal law. If that happens, the Texas Senate will enter the 2027 session armed with both a state-level prohibition narrative and a harder federal environment to cite in support of further restrictions.
For prohibition advocates, that is politically useful terrain. It allows them to argue that Texas is not overreacting, but merely aligning itself with an emerging trend. Whether that trend is analytically sound or opportunistically invoked is another question. In legislative combat, the appearance of alignment is often nearly as useful as the substance.
The Remaining Openings
None of this means the outcome is fixed in every respect. It means the structure of the fight is becoming clearer. Even in a hostile process, there are still places where the record can be contested and overreach can be exposed.
Kolkhorst’s history suggests some responsiveness to arguments grounded in genuine medical need, especially when voiced by patients, families, and veterans rather than by industry alone. That does not make her a reform ally. It does suggest that a purely commercial defense of the hemp market is less likely to break through than an argument grounded in access, inadequate alternatives, and the real-world consequences of prohibition.
The Sunset process may ultimately matter more than the interim hearings themselves. Sunset review is supposed to examine whether agencies are operating within legislative intent, using public resources rationally, and staying within the limits of their authority. That is a more fact-intensive forum than a THC hearing built around alarming testimony and politically convenient anecdotes. If opponents of overreach can show that DSHS exceeded its mandate, imposed irrational burdens, or failed to justify its regulatory choices, that case may carry more institutional force there than in a hearing designed from the outset to validate alarm.
The interim hearings will still matter, even if no one should mistake them for neutral proceedings. Their importance lies not in the prospect of immediate persuasion, but in the creation of a counter-record. Physicians, economists, public-health researchers, veterans, consumers, and lawful retailers can still inject complexity into a process designed to simplify. In Texas politics, that can make the difference between a one-sided morality play and a record robust enough to support litigation, legislative alternatives, and public skepticism.
What This Moment Really Means
The deeper significance of this moment is not simply that another committee has been assigned another study. It is that Texas leadership appears to be constructing, piece by piece, the procedural and rhetorical architecture for renewed action against THC products. The Legislature supplied the rhetoric. Agencies supplied the immediate pressure. Now the committee process is being positioned to supply the official justification.
For the broader public, that should raise a straightforward question. When lawmakers announce a “study,” are they seeking answers, or are they assembling evidentiary packaging for conclusions already chosen? On hemp-derived THC, the answer increasingly appears to be the latter. And with Lois Kolkhorst in the chair and Charles Perry at her side as vice chair, there is little reason to pretend this committee has been arranged for balance.
The next chapter of Texas hemp policy will not be decided in a single hearing room. It will be shaped in court, in agency review, in committee testimony, and in the wider political fight over whether regulation is still allowed to mean regulation, or whether every controversy must end the same way: with a ban dressed up as public health.
